↓ Skip to Main Content
  • About Glycorex
  • Contact
Glycorex Transplantation AB
  • sv 
  • en 

Search

  • Our products
  • Research & Innovation
  • Investors
  • Senaste pressmeddelande

    Fri, Jan 8 2021, 15:45 CET (Regulatory) Glycorex Transplantation AB (GTAB B): Bolagets UBP-produkt har bidragit till att rädda liv i samband med behandling av akut sjuka covid-19 patienter

    Läs fler pressmeddelanden »

  • Finansiella rapporter

    Fri, Nov 27 2020, 8:00 CET (Regulatory) Delårsrapport kvartal 3, 2020 (GTAB B)

    Fri, Aug 21 2020, 8:00 CET (Regulatory) Delårsrapport kvartal 2, 2020 (GTAB B)

    Wed, May 20 2020, 8:00 CET (Regulatory) Delårsrapport kvartal 1, 2020 (GTAB B)

    Se alla finansiella rapporter »

  • Aktieinformation

    Handelsinformation
    Glycorex-aktien är noterad och handlas på börsen Nordic Growth Market (NGM).
    Glycorex Transplantation AB noterades på NGM Equity Stockholm 2001.
    Symbol: GTAB B
    ISIN-kod: SE0000524530

World-leader in
ABO-incompatible technologies

When life starts again

Glycosorb®-ABO enables blood group incompatible transplants. Glycosorb®-ABO reduce anti-A/B antibodies in human plasma through A/B antigen specific binding. Glycosorb®-ABO has been used clinically since 2001. It is used on four continents and has enabled more than 4,500 blood group incompatible organ transplants.

Information about Coronavirus / Covid-19

The company's product can help increase the availability of blood plasma, including convalescent plasma, by removing the blood group antibodies from blood group O-, A- and B- donor plasma. 
In this way, potential problems with immune-complex formation with, for example, the administration of AB plasma (containing soluble AB antigen) can be avoided. 

A number of units of our product has been delivered to a European hospital.

 Please contact us for further information.

Intensive research

The Glycorex Group possesses unique know-how and proficiency in the fields of biologically active carbohydrate substances and extracorporeal blood treatment. This provides the foundation for the development work that the subsidiaries Glycoprobe and Glycorex UBP are doing in the fields of autoimmune diseases and universal blood plasma respectively.

© 2021 Glycorex Transplantation AB. All rights reserved.
This website uses cookies. Read more

The Glycorex Website (www.glycorex.se) contains information about products, which may or may not be available in any particular country, and if available, have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations, and medical practices governing the communication of medical or other information about medical products on the Internet. Nothing herein should be construed as a solicitation or promotion for any product, which is not authorized by the laws and regulations of the state or country where the reader resides. No Glycorex products are available for sales in the US at this point in time.
This website uses cookies to improve user experience. Read more Accept cookies